Leptospirosis

Leptospirosis is a severe and potentially life-threatening zoonotic disease caused by pathogenic bacteria belonging to the genus Leptospira. Our company offers a comprehensive suite of services aimed at accelerating the development of vaccines and therapies for leptospirosis.

Overview of Leptospirosis

The Leptospira genus consists of 68 validated species, many of which are capable of infecting a wide range of mammalian hosts, including humans. The disease transmission typically occurs through direct or indirect contact with the urine of infected animals, most commonly rodents. Once inside the human body, Leptospira can rapidly disseminate through the bloodstream, colonizing various organs and tissues, particularly the kidneys and liver, leading to the development of the hallmark manifestations of leptospirosis.

Fig.1 Current and potential therapeutic options for leptospirosis. (Petakh P., et al., 2024)

Vaccine Development for Leptospirosis

Scientific Challenges in Vaccine Development

The Leptospira genus is diverse, with over 300 serovars and 24 serogroups, complicating the development of a universal vaccine. The pathogen's ability to evade the immune system and adapt to various hosts adds further complexity. Despite the existence of vaccines for veterinary use, the development of a human vaccine has been hindered by the need for a broad cross-protective immune response.

Advances in Vaccine Candidates

Recent scientific advancements have focused on identifying novel protein targets through bioinformatics and reverse vaccinology. The leptospiral immunoglobulin-like (Lig) proteins have emerged as promising candidates due to their surface exposure and conservation among pathogenic species. Additionally, the exploration of live-attenuated vaccines has shown potential, with reports of efficacy and cross-protection.

Therapeutics Development for Leptospirosis

Our Services

By leveraging cutting-edge scientific methodologies and a deep understanding of leptospirosis pathogenesis, our company is well-positioned to contribute to the advancement of preventive and therapeutic strategies against this neglected disease. Through our preclinical research and development services, we aim to provide one-stop solutions for global pharmaceutical companies.

Vaccine Development

• Live-attenuated Vaccine
• Inactivated Vaccine
• Toxoid Vaccine
• Viral Vector Vaccine
• Virus-like Particles Vaccine
• Protein Subunit Vaccine
• mRNA Vaccine
• DNA Vaccine

Therapeutic Development

• Small Molecule Drug Development Services
• Therapeutic mRNA Development Services
• Therapeutic Antibody Development Services
• Cell Therapy Development Services

Infectious Disease Models

• Lethal Leptospirosis Models (Adult C57BL/6 mice deficient in TLR4 or MyD88)
• Sublethal Leptospirosis Models (A, CBA, BALB/c, C57BL/6, and C3H-HeJ mouse strains)
• Chronic Leptospirosis Models (Rattus norvegicus)

Our preclinical research services encompass a wide range of activities, from the identification of novel vaccine candidates through reverse vaccinology to the evaluation of their immunogenicity and protective efficacy in animal models. If our services have piqued your interest, we warmly welcome you to reach out to us for further information and to obtain a detailed quotation for the services you require.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.